X
Feb 24, 2022 08:39 AM (GMT+8) · EqualOcean
On February 23, Guangdong Pharmaceutical Trading Center issued the notice on viewing the information related to the registered products of Guangdong alliance diclofenac and other drugs purchased in a centralized manner (the first batch). A total of 174 varieties and 1613 products meet the application conditions. Among the recombinant human growth hormone varieties, 13 product specifications were successfully declared. Among them, there are four enterprises applying for powder injection dosage forms (human growth hormone for injection), including Jinsai Pharmaceutical Co., Ltd., a subsidiary of Changchun high tech, Anke biology, Zhongshan Weiming Haiji and Shanghai United Saier; The most concerned water injection type (recombinant human growth hormone injection) in the industry is only declared by Novo Nordisk, a multinational enterprise, and Changchun hi tech and Anke biology both abandoned the bid.